Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05566041 · ClinicalTrials.gov registry record · Phase 3
A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer
A Phase 3 study of Carcinoma, Small Cell Lung, sponsored by EpicentRx.
- Active
- Registry status
- Phase 3
- Development phase
- 292
- Enrollment target
- 2
- Study locations
NCT05566041 is a Phase 3 study of Carcinoma, Small Cell Lung that is active but no longer recruiting, run by EpicentRx. The registered enrollment target is 292 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT05566041, a Phase 3 study of Carcinoma, Small Cell Lung, is active but no longer recruiting, sponsored by EpicentRx.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 292 participants
- Enrollment target
- 2
- Study locations
Study Summary
This Global Phase 3 study aims to find out whether RRx-001 + platinum chemotherapy is more effective than platinum chemotherapy alone in 3rd line or beyond small cell cancer.
Conditions Studied
Interventions
- DRUG RRx-001 + eLOOP Device
- DRUG Cisplatin/carboplatin plus etoposide
Study Locations (2)
Florida
- H. Lee Moffitt Cancer Center & Research Institute, Inc. - Tampa
Kansas
- The University of Kansas Cancer Center - Westwood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 292 participants |
| Start Date | 2022-08-01 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05566041
The ClinicalTrials.gov registry entry for NCT05566041 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 292 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EpicentRx, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoma, Small Cell Lung appearing as the primary indexed condition, and to 2 interventions - of which RRx-001 + eLOOP Device is the first listed.
NCT05566041 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Kansas.
Frequently Asked Questions
What is clinical trial NCT05566041 about?
NCT05566041 is a clinical study titled "A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer". This Global Phase 3 study aims to find out whether RRx-001 + platinum chemotherapy is more effective than platinum chemotherapy alone in 3rd line or beyond small cell cancer.
What is the current status of trial NCT05566041?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 292 participants. The study started on 2022-08-01. Estimated completion is 2025-12-31.
What conditions does trial NCT05566041 study?
This clinical trial studies the following conditions: Carcinoma, Small Cell Lung.
What interventions are being tested in trial NCT05566041?
The interventions under investigation include: RRx-001 + eLOOP Device (DRUG), Cisplatin/carboplatin plus etoposide (DRUG).
Who is sponsoring clinical trial NCT05566041?
This trial is sponsored by EpicentRx, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05566041 being conducted?
This trial has 2 study locations across Florida, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.